acer pharma limited
acer pharma limited Company Information
Company Number
10045381
Next Accounts
Dec 2024
Industry
Wholesale of pharmaceutical goods
Shareholders
jason yates
Group Structure
View All
Contact
Registered Address
units 5-7 tintagel way, aldridge, walsall, WS9 8ER
Website
-acer pharma limited Estimated Valuation
Pomanda estimates the enterprise value of ACER PHARMA LIMITED at £1.9m based on a Turnover of £3.6m and 0.54x industry multiple (adjusted for size and gross margin).
acer pharma limited Estimated Valuation
Pomanda estimates the enterprise value of ACER PHARMA LIMITED at £0 based on an EBITDA of £-129 and a 4.05x industry multiple (adjusted for size and gross margin).
acer pharma limited Estimated Valuation
Pomanda estimates the enterprise value of ACER PHARMA LIMITED at £7.3m based on Net Assets of £3.7m and 1.98x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Acer Pharma Limited Overview
Acer Pharma Limited is a live company located in walsall, WS9 8ER with a Companies House number of 10045381. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in March 2016, it's largest shareholder is jason yates with a 100% stake. Acer Pharma Limited is a young, small sized company, Pomanda has estimated its turnover at £3.6m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Acer Pharma Limited Health Check
Pomanda's financial health check has awarded Acer Pharma Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
4 Regular
5 Weak
Size
annual sales of £3.6m, make it smaller than the average company (£25.7m)
- Acer Pharma Limited
£25.7m - Industry AVG
Growth
3 year (CAGR) sales growth of -21%, show it is growing at a slower rate (4.9%)
- Acer Pharma Limited
4.9% - Industry AVG
Production
with a gross margin of 23.5%, this company has a comparable cost of product (23.5%)
- Acer Pharma Limited
23.5% - Industry AVG
Profitability
an operating margin of 0% make it less profitable than the average company (3.6%)
- Acer Pharma Limited
3.6% - Industry AVG
Employees
with 6 employees, this is below the industry average (38)
- Acer Pharma Limited
38 - Industry AVG
Pay Structure
on an average salary of £66.4k, the company has an equivalent pay structure (£66.4k)
- Acer Pharma Limited
£66.4k - Industry AVG
Efficiency
resulting in sales per employee of £600.4k, this is equally as efficient (£644.7k)
- Acer Pharma Limited
£644.7k - Industry AVG
Debtor Days
it gets paid by customers after 72 days, this is near the average (60 days)
- Acer Pharma Limited
60 days - Industry AVG
Creditor Days
its suppliers are paid after 99 days, this is slower than average (34 days)
- Acer Pharma Limited
34 days - Industry AVG
Stock Days
it holds stock equivalent to 2 days, this is less than average (58 days)
- Acer Pharma Limited
58 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (9 weeks)
0 weeks - Acer Pharma Limited
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 23%, this is a lower level of debt than the average (56.8%)
23% - Acer Pharma Limited
56.8% - Industry AVG
ACER PHARMA LIMITED financials
Acer Pharma Limited's latest turnover from March 2023 is estimated at £3.6 million and the company has net assets of £3.7 million. According to their latest financial statements, we estimate that Acer Pharma Limited has 6 employees and maintains cash reserves of £2.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|
| Turnover | |||||||
| Other Income Or Grants | |||||||
| Cost Of Sales | |||||||
| Gross Profit | 1,200,055 | 2,808,956 | |||||
| Admin Expenses | 335,601 | 2,581,430 | |||||
| Operating Profit | 864,454 | 227,526 | |||||
| Interest Payable | 0 | 0 | |||||
| Interest Receivable | 6,295 | 0 | |||||
| Pre-Tax Profit | 923,175 | 2,275,286 | |||||
| Tax | -178,347 | -435,237 | |||||
| Profit After Tax | 744,828 | 1,840,049 | |||||
| Dividends Paid | 0 | 0 | |||||
| Retained Profit | 744,828 | 1,840,049 | |||||
| Employee Costs | |||||||
| Number Of Employees | 1 | 3 | 5 | 2 | |||
| EBITDA* | 876,693 | 234,336 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 4,505 | 12,892 | 21,436 | 26,865 | 32,175 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 2,315,000 | 2,315,000 | 2,540,000 | 0 | 0 | 0 | 500,000 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 2,315,000 | 2,315,000 | 2,544,505 | 12,892 | 21,436 | 26,865 | 532,175 |
| Stock & work in progress | 15,410 | 0 | 44,015 | 0 | 0 | 0 | 20,634 |
| Trade Debtors | 712,583 | 1,603,292 | 1,370,732 | 1,688,160 | 742,033 | 2,302,873 | 1,129,756 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 1,716,510 | 1,716,510 | 216,510 | 0 | 873,510 | 0 | 0 |
| Cash | 2,686 | 3,353 | 24,380 | 607,193 | 417,679 | 1,216,036 | 191,158 |
| misc current assets | 0 | 0 | 0 | 2,540,000 | 2,540,000 | 1,800,000 | 0 |
| total current assets | 2,447,189 | 3,323,155 | 1,655,637 | 4,835,353 | 4,573,222 | 5,318,909 | 1,341,548 |
| total assets | 4,762,189 | 5,638,155 | 4,200,142 | 4,848,245 | 4,594,658 | 5,345,774 | 1,873,723 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 748,054 | 993,192 | 466,870 | 1,112,312 | 858,725 | 2,054,184 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 300,485 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 347,606 | 978,433 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 1,095,660 | 1,971,625 | 466,870 | 1,112,312 | 858,725 | 2,354,669 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 722,667 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 722,667 |
| total liabilities | 1,095,660 | 1,971,625 | 466,870 | 1,112,312 | 858,725 | 2,354,669 | 722,667 |
| net assets | 3,666,529 | 3,666,530 | 3,733,272 | 3,735,933 | 3,735,933 | 2,991,105 | 1,151,056 |
| total shareholders funds | 3,666,529 | 3,666,530 | 3,733,272 | 3,735,933 | 3,735,933 | 2,991,105 | 1,151,056 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Profit | 864,454 | 227,526 | |||||
| Depreciation | 0 | 4,505 | 8,387 | 6,810 | 6,810 | 8,043 | |
| Amortisation | 0 | 0 | 0 | 5,429 | 0 | 0 | |
| Tax | -178,347 | -435,237 | |||||
| Stock | 15,410 | -44,015 | 44,015 | 0 | 0 | -20,634 | 20,634 |
| Debtors | -890,709 | 1,732,560 | -100,918 | 72,617 | -687,330 | 1,173,117 | 1,129,756 |
| Creditors | -245,138 | 526,322 | -645,442 | 253,587 | -1,195,459 | 2,054,184 | 0 |
| Accruals and Deferred Income | -630,827 | 978,433 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 190,217 | 700,800 | |||||
| Investing Activities | |||||||
| capital expenditure | |||||||
| Change in Investments | 0 | -225,000 | 2,540,000 | 0 | 0 | -500,000 | 500,000 |
| cash flow from investments | |||||||
| Financing Activities | |||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | -300,485 | 300,485 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | -722,667 | 722,667 |
| share issue | |||||||
| interest | 6,295 | 0 | |||||
| cash flow from financing | -294,190 | -422,182 | |||||
| cash and cash equivalents | |||||||
| cash | -667 | -21,027 | -582,813 | 189,514 | -798,357 | 1,024,878 | 191,158 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -667 | -21,027 | -582,813 | 189,514 | -798,357 | 1,024,878 | 191,158 |
acer pharma limited Credit Report and Business Information
Acer Pharma Limited Competitor Analysis
Perform a competitor analysis for acer pharma limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in WS9 area or any other competitors across 12 key performance metrics.
acer pharma limited Ownership
ACER PHARMA LIMITED group structure
Acer Pharma Limited has no subsidiary companies.
Ultimate parent company
ACER PHARMA LIMITED
10045381
acer pharma limited directors
Acer Pharma Limited currently has 2 directors. The longest serving directors include Mr Jason Yates (Mar 2016) and Mr Ian Pritchard (Oct 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Jason Yates | England | 51 years | Mar 2016 | - | Director |
| Mr Ian Pritchard | 54 years | Oct 2023 | - | Director |
P&L
March 2023turnover
3.6m
-63%
operating profit
-129.3
0%
gross margin
23.6%
+3.24%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
3.7m
0%
total assets
4.8m
-0.16%
cash
2.7k
-0.2%
net assets
Total assets minus all liabilities
acer pharma limited company details
company number
10045381
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
March 2016
age
8
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2023
previous names
N/A
accountant
-
auditor
-
address
units 5-7 tintagel way, aldridge, walsall, WS9 8ER
Bank
-
Legal Advisor
-
acer pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 6 charges/mortgages relating to acer pharma limited. Currently there are 6 open charges and 0 have been satisfied in the past.
acer pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
